Here’s What Else We Know About the White House Meetings On CBD
The discussions come as the FDA crafts its enforcement policy on CBD
New details have been released on the CBD-focused meetings taking place at the White House, on which Cannabis Wire first reported last month. The topic of discussion? The US Food and Drug Administration’s forthcoming guidance on CBD products.
On July 22, the FDA submitted to the White House Office of Management and Budget (OMB) its “Cannabidiol Enforcement Policy; Draft Guidance for Industry; Availability.” This is the last step in a winding, months-long process that began following the passage of the 2018 Farm Bill, which legalized cannabis plants with .3% THC or less, and all non-THC cannabinoids within the cannabis plant. Once the OMB signs off on these guidelines, the published policy will place guardrails around the growing, but mostly unregulated, CBD industry.
(Cannabis Wire has been closely covering the FDA’s deliberations on CBD policy. Read all of our original reporting and analysis here.)
Already, as Cannabis Wire reported, three entities met with White House on CBD: on July 30, the US Hemp Roundtable; on July 31, the National Industrial Hemp Council; on August 3, Ziese Farms, a hemp farm in Washington state.
Now, several new names have appeared on the meeting schedule. Two of those meeting dates have passed: attorney Jessica Wasserman was joined by Steve Bevan, a founder of GenCanna Global and a founding chair of US Hemp Roundtable, who met with the White House as an individual, and by Ron Conyea of Conyea Farms, on August 6; and the American Herbal Products Association, on August 4. Forthcoming meetings have been scheduled with: Tami Wahl, former council of the American Herbal Products Association for Monday, August 11; Vote Hemp for August 13; dietary supplement company Pharmavite LLC for August 14; and Geoff Whaling for August 17.
To Read The Rest Of This Article On Cannabis Wire, Click Here
